Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (431-440 of 713) with videos related to

Pageof 72
Sort By:
American Journal of Hematology|May 12, 2017
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemiaBrittany Knick Ragon, Naval Daver, Guillermo Garcia-Manero, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2016
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of MyelodysplasiaKoji Sasaki, Elias Jabbour, Jorge Cortes, et al.
Cancer|August 4, 2005
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cellsSrdan Verstovsek, Mirna Golemovic, Hagop Kantarjian, et al.
Leukemia & Lymphoma|July 23, 2014
Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factorYiming Chen, Zeev Estrov, Sherry Pierce, et al.
The Lancet. Haematology|October 6, 2015
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 studyPreetesh Jain, Hagop Kantarjian, Elias Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 12, 2016
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML PatientsKoichi Takahashi, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Cancer|April 15, 2005
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experienceHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Haematologica|July 2, 2013
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 monthsAziz Nazha, Hagop Kantarjian, Preetesh Jain, et al.
British Journal of Haematology|January 17, 2007
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemiaFrancis J Giles, Gautam Borthakur, Farhad Ravandi, et al.
Blood|March 14, 2009
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phaseCarmen Fava, Hagop M Kantarjian, Elias Jabbour, et al.
Pageof 72

Showing results (431-440 of 713) with videos related to

Sort By:
Pageof 72
American Journal of Hematology|May 12, 2017
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemiaBrittany Knick Ragon, Naval Daver, Guillermo Garcia-Manero, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2016
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of MyelodysplasiaKoji Sasaki, Elias Jabbour, Jorge Cortes, et al.
Cancer|August 4, 2005
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cellsSrdan Verstovsek, Mirna Golemovic, Hagop Kantarjian, et al.
Leukemia & Lymphoma|July 23, 2014
Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factorYiming Chen, Zeev Estrov, Sherry Pierce, et al.
The Lancet. Haematology|October 6, 2015
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 studyPreetesh Jain, Hagop Kantarjian, Elias Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 12, 2016
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML PatientsKoichi Takahashi, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Cancer|April 15, 2005
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experienceHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Haematologica|July 2, 2013
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 monthsAziz Nazha, Hagop Kantarjian, Preetesh Jain, et al.
British Journal of Haematology|January 17, 2007
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemiaFrancis J Giles, Gautam Borthakur, Farhad Ravandi, et al.
Blood|March 14, 2009
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phaseCarmen Fava, Hagop M Kantarjian, Elias Jabbour, et al.
Pageof 72